Acquisition of expanded indications for intravenous cyclophosphamide in the management of childhood rheumatic disease in general
- 16 April 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 21 (5) , 449-457
Abstract
We created the final bill of “Intravenous cyclophosphamide (IVCY) for the treatment of rheumatic disease of children in general” in order to get approval for the off-label use of IVCY from the Study Group on Pediatric Drug Therapy. As a result, this study group approved IVCY’s off-label use in children via public applications. We could create IVCY regimen specific for Japanese children independently of the efficacy, dosage, and administration applied in Germany, which at the time of application was the only country in Europe and the USA where IVCY was approved. Later, its use in adults was given approval through public applications after being fully reviewed by the Study Group on Unapproved and Off-label Drugs of High Medical Need. Consequently, IVCY is now available for the treatment of both childhood and adult rheumatic diseases in general.Keywords
This publication has 17 references indexed in Scilit:
- Review: Systemic lupus erythematosus in children: current and emerging therapiesLupus, 2007
- Targeted B-Cell Depletion Therapy in Childhood-Onset Systemic Lupus ErythematosusPediatric Drugs, 2007
- Juvenile polyarteritis: Results of a multicenter survey of 110 childrenThe Journal of Pediatrics, 2004
- Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosusClinical Rheumatology, 2004
- Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosisArthritis & Rheumatism, 2003
- Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisoloneLupus, 2003
- Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty‐five patientsArthritis Care & Research, 2003
- High‐dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosusArthritis & Rheumatism, 2003
- Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritisThe Lancet, 1992
- Intermittent intravenous cyclophosphamide therapy for lupus nephritisThe Journal of Pediatrics, 1989